Digisonics, a clinical image management provider, and Medis, a private software solution provider, have announced a partnership to create an image analysis and structured reporting tool for adult and pediatric cardiovascular MR studies. The Medis QMass ES has received approval from the Food and Drug Administration (FDA).
The system allows users to analyze cardiovascular dimensions and morphology, myocardial function (MR & CT), phase-contrast blood flow, tissue characterization (late enhancement, T2 weighted edema, T1 and T2 mapping), myocardial perfusion, and MR angiography. The myocardial perfusion and tissue characterization modules have not yet received 501(k) clearance. Once analysis is complete, clinicians can save the results into configurable, structured reports and can embed processed images and graphics.
“Digisonics is excited to partner with Medis in offering the most comprehensive combination of Cardiac MR imaging and reporting functionality on the market,” said Steve Dissing, Director of Sales and Marketing at Digisonics. “Combining Digisonics’ 39 years of experience in structured reporting with the MR imaging toolset from Medis will provide clinicians and researchers the comprehensive analysis, reporting and data mining capabilities they require.”
For more information, visit Digisonics and Medis.
